Epitomee Medical

Epitomee Medical Ltd. is an Israeli public company that develops, manufactures, and commercializes ingestible therapeutic devices packaged in standard-size capsules. The company was founded in August 2005 under the name Tulip Biotechnology Ltd. and changed its name to Epitomee Medical Ltd. in July 2018. It is headquartered in the Caesarea Industrial Park in Israel. The company is led by CEO Dolev Rafaeli, with co-founder Shimon Eckhouse serving as active Chairman of the Board. Epitomee's core technology is a platform of ingestible devices that are self-ingested in a swallowable capsule. Once swallowed, the device deploys in targeted regions along the gastrointestinal tract — the stomach, duodenum, and small intestine — where it provides mechanosensory stimulation, targeted drug delivery, or absorption management. The device has a set duration of activity, after which it dissolves and is evicted through natural bowel movements. The company describes its approach as "designed with anatomy in mind" and aims to treat chronic diseases through a self-managed, safer, and more manageable alternative to existing therapies. The company's lead program is a weight-management device: a capsule that, upon contact with stomach juices, expands and spreads to give the patient a feeling of satiety and prevent overeating. Epitomee is also developing devices for the delivery of biologic drugs through the wall of the small intestine as an alternative to injection. In December 2021, Epitomee completed an initial public offering on the Tel Aviv Stock Exchange, raising ILS 185 million at a pre-money valuation of ILS 632 million. At the time of the IPO, the company had not yet begun commercial manufacturing of its weight-loss capsule, but it had signed an agreement with the medical nutrition division of Nestlé for exclusive worldwide marketing and distribution of the capsule. In November 2023, Nestlé informed Epitomee that the clinical trial results for the weight-loss capsule did not meet predefined threshold conditions, and that it did not intend to pay Epitomee the $10 million that had been promised for meeting those thresholds. In September 2026, the Israel Securities Authority imposed financial sanctions on the company and its officers for the negligent inclusion of misleading details in the company's reports from the end of 2023. The sanctions amounted to ILS 1.3 million for the company, ILS 300,000 for outgoing CEO Dr. Dan Hashmoni, and ILS 250,000 for Chairman Dr. Shimon Eckhouse. The company holds patents and patent applications for its developments.

Epitomee Medical Ltd. was founded in August 2005 under the name Tulip Biotechnology Ltd. by Dr. Shimon Eckhouse and Doron Marco. In July 2018, the company changed its name to Epitomee Medical Ltd. The company is headquartered in the Caesarea Industrial Park in Israel. In September 2008, the company completed a fundraising round of $8 million. By December 2021, the company employed 37 people. In December 2021, Epitomee Medical completed an initial public offering on the Tel Aviv Stock Exchange, raising ILS 185 million at a pre-money valuation of ILS 632 million. At the time of the IPO, the company had not yet begun commercial manufacturing of its weight-loss capsule, but it had signed an agreement with the medical nutrition division of Nestlé for exclusive worldwide marketing and distribution of the capsule. In November 2023, Nestlé informed Epitomee that the clinical trial results for the weight-loss capsule did not meet predefined threshold conditions, and that it did not intend to pay Epitomee the $10 million that had been promised for meeting those thresholds. In September 2026, the Israel Securities Authority imposed financial sanctions on the company and its officers due to the negligent inclusion of misleading details in the company's reports from the end of 2023. The sanctions amounted to ILS 1.3 million for the company, ILS 300,000 for outgoing CEO Dr. Dan Hashmoni, and ILS 250,000 for Chairman Dr. Shimon Eckhouse. The company holds patents and patent applications for its developments. Its core technology is a platform of ingestible devices that are self-ingested in a swallowable capsule and deploy in targeted regions along the gastrointestinal tract for mechanosensory stimulation, targeted drug delivery, and absorption management. The lead program is a weight-management device that expands upon contact with stomach juices to provide a feeling of satiety. The company is also developing devices for the delivery of biologic drugs through the wall of the small intestine as an alternative to injection.

• Company founded as Tulip Biotechnology Ltd. by Shimon Eckhouse and Doron Marco.

• Completed a fundraising round of $8 million.

• Changed name to Epitomee Medical Ltd.

• Completed IPO on the Tel Aviv Stock Exchange, raising ILS 185 million at a pre-money valuation of ILS 632 million.

• Nestlé informed Epitomee that clinical trial results for the weight-loss capsule did not meet thresholds and that it would not pay the $10 million promised.

• Israel Securities Authority imposed financial sanctions on the company and its officers for negligent misleading details in 2023 reports.

Developer of paradigm-shifting ingestible devices for chronic disease management, offering self-managed, safer, and kinder-to-the-system alternatives.

• Weight management capsule

  A swallowable capsule that expands upon contact with stomach juices to provide a feeling of satiety and prevent overeating.

• Biologics delivery device

  A device designed to deliver biologic drugs through the wall of the small intestine as an alternative to injection.

1. 1Epitomee - Shaping your healthepitomeemedical.com
2. 2About - Epitomeeepitomeemedical.com
3. 3Epitomee Medical Ltd - Wikidatawikidata.org
4. 4אפיטומי מדיקל - Wikipedia (Hebrew)he.wikipedia.org